Carl Zeiss Meditec ((GB:0DHC)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Carl Zeiss Meditec AG is conducting a study titled ‘EPIC: Evaluation of the Postoperative Cataract Surgery Outcomes in Patients With Prior Corneal Laser Vision Correction Implanted With the CT LUCIA Intraocular Lens.’ The study aims to assess the visual and refractive outcomes in patients who have undergone laser vision correction and are now receiving the CT LUCIA intraocular lens during cataract surgery. This research is significant as it evaluates the effectiveness of the CT LUCIA lens in improving visual quality post-surgery.
Intervention/Treatment: The intervention involves the use of the CT LUCIA 621P intraocular lens, a device designed to enhance visual quality and refractive stability in patients undergoing cataract surgery. This lens is implanted during routine surgery for patients with a history of myopic corneal laser vision correction.
Study Design: This is an observational, prospective cohort study. It does not involve random allocation or masking, focusing instead on following patients over time to observe outcomes. The primary purpose is to gather data on postoperative visual and refractive outcomes.
Study Timeline: The study began on July 15, 2025, with the latest update submitted on July 22, 2025. These dates are crucial as they mark the commencement and recent progress of the study, indicating its active status and ongoing recruitment.
Market Implications: The outcomes of this study could influence Carl Zeiss Meditec’s stock performance positively if the CT LUCIA lens proves effective, enhancing investor confidence. Success in this study might also position the company favorably against competitors in the ophthalmic device market, potentially increasing its market share.
The study is ongoing, with further details available on the ClinicalTrials portal.